IMGN’s 150% EPS surprise highlights improving operational efficiency, though the -204.93% profit margin underscores significant ongoing cash burn typical of its high-growth biotech phase.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2023-11-02 | Q3 2023 | 0.04 | 0.10 | +150.00% | $113.4M | ✅ Beat | +3.75% | +5.35% | +96.25% |
| 2023-07-31 | Q2 2023 | -0.16 | -0.02 | +87.50% | $83.2M | ✅ Beat | -8.71% | -12.60% | -20.39% |
| 2023-04-28 |
| Q1 2023 |
| -0.25 |
| -0.16 |
| +36.00% |
| $49.9M |
| ✅ Beat |
| +24.77% |
| +207.41% |
| +224.07% |
| 2023-03-01 | Q4 2022 | -0.30 | -0.23 | +23.33% | $41.2M | ✅ Beat | +3.61% | +8.25% | -1.29% |
Showing last 4 quarters.